What did Fisher & Paykel Healthcare Corporation Limited announce?

Fisher & Paykel Healthcare Corporation Limited (NZX: FPH) filed “2026 Annual Shareholders Meeting Speeches and Presentation” with NZX on 24 August 2026, as an agm announcement.

From the announcement:“Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) has provided the attached Chair’s speech and CEO’s slide presentation for the 2026 Annual Shareholders’ Meeting today.”
When was it filed?
24 August 2026
Where is the original?
NZX announcement
Fisher & Paykel Healthcare Corporation Limited logo

2026 Annual Shareholders Meeting Speeches and Presentation

AGM24 August 2026FPHHealthcare

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)


2026 Annual Shareholders’ Meeting Speech and Presentation


Auckland, New Zealand, 25 August 2026 – Fisher & Paykel Healthcare Corporation Limited (NZX:FPH,

ASX:FPH) has provided the attached Chair’s speech and CEO’s slide presentation for the 2026 Annual

Shareholders’ Meeting today.


There is no new material information contained within the speech or the presentation.


The speech and presentation are available on the company’s website at:

www.fphcare.com/nz/corporate/investor/events/.


Fisher & Paykel Healthcare’s Annual Shareholders’ Meeting is scheduled for 2pm NZST, 12pm AEST

(10pm USEDT) on Tuesday 25 August. To participate, go to: www.virtualmeeting.co.nz/fph26.



About Fisher & Paykel Healthcare


Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems

for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The

company’s products are sold in over 120 countries worldwide. For more information about the

company, visit our website www.fphcare.com.



Contacts


Media

Karen Knott

GM Corporate Communications

karen.knott@fphcare.co.nz

+64 21 713 911

Investors

Daniel Adolph

Head of Investor Relations

daniel.adolph@fphcare.co.nz

+64 22 511 4050



Authorised by Raelene Leonard, General Counsel and Company Secretary.

---

1
FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

ANNUAL SHAREHOLDERS’ MEETING

25 AUGUST 2026

ADDRESS BY NEVILLE MITCHELL

BOARD CHAIR

Ladies and gentlemen, it is a privilege to address you again as Chair of your Board. In my address today, I

will share the Board's perspective on the company's progress and long-term priorities. Lewis will then

provide more detail on our financial and operational performance.

Fisher & Paykel Healthcare is guided by a unifying purpose – improving care and outcomes of patients.

One measure of success is the number of patients who benefit from our products and therapies. Last year,

this number was approximately 24 million people worldwide.

It was also another strong year financially. For the 2026 financial year, operating revenue increased to

$2.31 billion, net profit after tax increased to $468.5 million, and the Board approved total dividends of 52

cents per share. These outcomes reflect the strength of a business that has been built over many years

across products, therapies, geographies and markets.

In this industry, long-term value is created by continuing to improve products, expand clinical

understanding, and identify new ways to support patients and clinicians. Our shareholders will be familiar

with our strong commitment to research and development. In the 2026 financial year, the company invested

$235.5 million in R&D. This level of investment is critical to sustaining innovation, expanding our clinical

impact and ensuring a strong pipeline of future products.

Product innovation requires talented people, specialised equipment and spaces for collaboration,

development and testing. Here at our East Tāmaki campus, you can see that work has progressed on our

fifth building. The new facility will provide additional space for product development, manufacturing and

warehousing, and it is on track to open around the middle of 2027.

As a Board, we remain disciplined in our approach to major capital investments. You may recall that we

have purchased land to develop a second New Zealand campus in Karaka, and we continue to see this as

an attractive location. We also see opportunities for growth beyond New Zealand. As directors, spending

time in the regions where we operate is an important part of our oversight responsibility, and last year, the

Board visited our operations in China. We gained a deeper understanding of one of the world's fastest-

growing healthcare markets and engaged directly with key people there. Over the next year, we will be

looking to expand our manufacturing footprint in China to complement our ongoing investment in New

Zealand, Mexico and other regions.

2
As the company continues to grow, maintaining our culture globally becomes increasingly important. The

people of Fisher & Paykel Healthcare care deeply about patients, as well as their coworkers. They have a

relentless desire to improve, value original thinking, approach their work with humility, and work together for

the greater good. We believe the culture remains one of the company's greatest strengths and an important

contributor to long-term performance. Your Board recognises this and continues to monitor our progress.

I would now like to cover a few other matters that have received attention from the Board this year.

First, the topic of sustainable procurement and addressing modern slavery risks. This year, New Zealand

introduced a Modern Slavery Bill into Parliament that would create a regulatory framework requiring large

organisations to identify, address, and report on modern slavery risks within their operations and supply

chains. We believe companies have a responsibility to understand the conditions under which their

products are made and sourced, and we have robust processes in place to guide procurement decisions.

As part of our belief in “doing the right thing,” we work with our suppliers to raise awareness about modern

slavery risks and support them to address this issue. We already report under Australian, British and

Canadian legislation on this matter.

Second, an update on the composition of the Board. Last year we farewelled Pip Greenwood, and Anna

Curzon was appointed in February. Anna has brought a wealth of knowledge in the technology and

financial services industries to the Board. She is up for election today and will speak to you later in the

agenda. We continue to support the Future Directors programme, and we were fortunate to welcome

Margie Apa as our Future Director for this term. You may already be familiar with Margie, as she is the

former CEO of Health New Zealand.

Third, ahead of the vote today, I would like to say a few words on non-executive director remuneration. As

shareholders would expect, attracting and retaining high-calibre directors is important for effective

governance. The Board periodically reviews non-executive director remuneration with the assistance of

external advisers to ensure it remains appropriate for the responsibilities involved and competitive with

comparable organisations. This year, we have recommended changes in director remuneration, and these

are outlined in Explanatory Note 3 of the Notice of Meeting.

In closing, I would like to return to a theme I discussed last year: long-term thinking.

We are operating in a world that is increasingly complex. F&P operates in over 120 different countries, so

world events are important. Supply chains remain exposed to disruption. Healthcare systems are under

pressure. Geopolitics, trade policies and tariffs have continued to be important considerations. We do not

underestimate these challenges; they require careful oversight and steady decision-making. We have

3
continued to follow these issues closely and have met with experts in New Zealand and overseas to

navigate them. In this regard, we acknowledge MFAT and the advice they provide us.

We cannot control external events, but we can maintain our long-term view. This guides our decisions. The

company’s success does not rest on a single year’s performance. It rests on a consistent strategy,

innovative products, a strong culture, and trust earned over many years. Those are the foundations the

Board is focused on protecting and strengthening.

On behalf of the Board, thank you to our people, customers, suppliers and shareholders for your continued

support.

ADDRESS BY LEWIS GRADON

MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

Please refer to separate slide presentation.

---

1
Annual Shareholders' Meeting

25 August 2026

2
Mark Cross

Your Board

Neville MitchellLewis Gradon

Sir Michael Daniell

Anna Curzon

Cather Simpson

Graham McLean

Lisa McIntyre

3
Agenda

•Chair’s Address

•Managing Director and Chief Executive Officer’s Address

•Financial Statements

•Resolutions

•Voting

•General Questions

4
Neville Mitchell

Board Chair

NZ Campus 1 - Building 5
28,000 m

2

/ 300,000 ft

2

NZ Campus 2 - Karaka
Future second campus in South Auckland

7

8
Mark Cross

Your Board

Neville MitchellLewis Gradon

Sir Michael Daniell

Anna Curzon

Cather Simpson

Graham McLean

Lisa McIntyre

9
Anna Curzon

New director

10
Margie Apa

Future Director

11
Neville Mitchell

Board Chair

12
Lewis Gradon

Managing Director

and CEO

13
FY26 financial highlights

Operating Revenue

$2.31B12% (cc)

Net Profit After Tax

$468.5M28% (cc)

Constant currency growth rates

Gross Margin

63.7%

122

bps

Hospital Hardware

27% (cc)

14
10-year trends

Constant currency growth rates

$0.0b

$0.5b

$1.0b

$1.5b

$2.0b

$2.5b

1617181920212223242526

Revenue

FY26

$2.31B

12%

$0m

$100m

$200m

$300m

$400m

$500m

$600m

1617181920212223242526

Net Profit After Tax

FY26

$468.5M

28%

15
Dividends

0c

10c

20c

30c

40c

50c

60c

20162017201820192020202120222023202420252026

CPS (NZ cents)

Interim CPSFinal CPSTotal CPS

FY26 Final Dividend

33cps

38%

FY26 Total Dividend

52cps

22%

Dividend history FY16 - FY26

10-year DPS CAGR

12%

Global trade and
world events

17
FY27 first half outlook

At 31 July exchange rates*, guidance assumptions for the first half of the 2027 financial

year include a continuation of the current trading environment and result in:

•Operating revenue of approximately $1.24 billion

•Net profit after tax of approximately $280 million.

This would equate to approximately 14% growth in reported operating revenue and

approximately 24% growth in net profit after tax (excluding the impact of US tariff

refunds), compared to the first half of the 2026 financial year.

*31 July 2026 exchange rates of NZD:USD 0.59, NZD:EUR 0.51, NZD:MXN 10.17.

18
FY27 full year outlook

At 31 July exchange rates*, our full year guidance is for:

•Operating revenue in the range of approximately $2.47 billion to $2.57 billion

•Net profit after tax in the range of approximately $525 million to $565 million.

The first half and full year net profit after tax guidance incorporates $23 million in US

IEEPA tariff refunds.

The full year outlook assumes current global tariff rates, policies and applications for

the duration of this financial year and continues to anticipate an overall improvement in

gross margin.

*31 July 2026 exchange rates of NZD:USD 0.59, NZD:EUR 0.51, NZD:MXN 10.17.

19
Building momentum for the future

FY2021FY2026ChangeComment

People in Research & Development68496942%

R&D spend averaging 10.6% of

revenue over five years.

Patents in the United States381768102%

Our global patent portfolio now

numbers more than 4,500.

People in Sales, Marketing &

Distribution

1,2301,56827%

A direct sales presence in 55 countries

vs. 45 in FY21.

Nasal high flow (NHF) clinical practice

guidelines

512+7

~3,200 studies cumulatively published

over five years.

Number of professional societies or

groups with anesthesia guidelines

recommending/acknowledging NHF

~10~25+~15

Guidelines span several strategic

markets including North America, UK,

France, and Australia/NZ.

Hospital hardware revenueApproximately ~$880m in cumulative hospital hardware revenue from FY2022 to FY2026.

20
Gross margin recovery

45%

50%

55%

60%

65%

FY22FY23FY24*FY25FY26

Our 5-year margin history

Long-term gross margin target

*Underlying gross margin excludes the product recall provision

21
Revenue growth since 2001

$0

$500

$1,000

$1,500

$2,000

$2,500

200120062011201620212026

Revenue (NZ$m)

Revenue in NZ$ millions by financial year

~24 million patients

$2.31 billion revenue

22
Neville Mitchell

Board Chair

23
Financial statements

•Opportunity for shareholders to ask any questions specifically on the financial

statements, the auditor’s report or the company’s 2026 annual report.

•There will be an opportunity to ask any general questions once all items on the

agenda have been considered.

24
Resolutions

1.Election of Anna Curzon

2.Auditor’s Remuneration

3.Directors’ Remuneration

4.Discretionary Long Term Variable Remuneration to Lewis Gradon

5.Issue of Performance Share Rights – North America

6.Issue of Share Options – North America

7.Issue of Employee Share Rights – North America

25
How to vote online

Voting box

Question box

Help line

26
Neville Mitchell

Board Chair

27
Resolution 1: Election of Anna Curzon

That Anna Curzon, who being eligible,

offers herself for election, be elected as a

Director of the company.

Click “Submit Vote” to lodge your vote.

Need help?

Call the MUFG Corporate Markets helpline

0800 200 220

28
Resolution 2: Auditor’s Remuneration

That the Directors be authorised to fix the

fees and expenses of PwC as the

company’s auditor.

Click “Submit Vote” to lodge your vote.

Need help?

Call the MUFG Corporate Markets helpline

0800 200 220

29
Resolution 3: Directors’ Remuneration

That the maximum aggregate annual

remuneration payable to non-executive

Directors be increased by NZ$350,000

from NZ$1,750,000 to NZ$2,100,000

(plus GST as appropriate).

Click “Submit Vote” to lodge your vote.

Need help?

Call the MUFG Corporate Markets helpline

0800 200 220

30
Resolution 4: Discretionary Long Term Variable Remuneration

That the grant of discretionary long term

variable remuneration instruments to

Lewis Gradon, Managing Director and

Chief Executive Officer, be approved.

Click “Submit Vote” to lodge your vote.

Need help?

Call the MUFG Corporate Markets helpline

0800 200 220

31
Resolution 5: Issue of Performance Share Rights

That the Fisher & Paykel Healthcare

Corporation Limited 2025 Performance

Share Rights Plan – North America be

approved.

Click “Submit Vote” to lodge your vote.

Need help?

Call the MUFG Corporate Markets helpline

0800 200 220

32
Resolution 6: Issue of Share Options

That the Fisher & Paykel Healthcare

Corporation Limited 2025 Share Option

Plan – North America be approved.

Click “Submit Vote” to lodge your vote.

Need help?

Call the MUFG Corporate Markets helpline

0800 200 220

33
Resolution 7: Issue of Employee Share Rights

That the Fisher & Paykel Healthcare

Corporation Limited Employee Share

Rights Plan – North America be approved.

Click “Submit Vote” to lodge your vote.

Need help?

Call the MUFG Corporate Markets helpline

0800 200 220

34
Neville Mitchell

Board Chair

35
Questions

Questions

36
Thank you for attending today’s

Annual Shareholders' Meeting

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.